U.S. markets closed

ContraFect Corporation (CFRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.8400-0.1200 (-3.03%)
At close: 4:00PM EDT

ContraFect Corporation

28 Wells Avenue
3rd Floor
Yonkers, NY 10701
United States
914 207 2300
http://www.contrafect.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees33

Key Executives

NameTitlePayExercisedYear Born
Dr. Roger James Pomerantz F.A.C.P., FACP, M.D.Chairman, CEO & Pres1.37MN/A1957
Mr. Michael Messinger CPA, CPAChief Financial Officer623.3kN/A1975
Dr. Cara M. CassinoChief Medical Officer and Exec. VP of R&D883.15kN/A1962
Ms. Natalie Bogdanos J.D.Gen. Counsel, Corp. Sec. & Data Protection OfficerN/AN/A1969
Dr. Gary WoodnuttSr. VP of Translational Sciences & Preclinical Devel.N/AN/A1957
Dr. Michael WittekindConsultantN/AN/A1955
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. The company has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. It also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. The company was incorporated in 2008 and is headquartered in Yonkers, New York.

Corporate Governance

ContraFect Corporation’s ISS Governance QualityScore as of July 1, 2021 is 8. The pillar scores are Audit: 3; Board: 7; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.